Detalles de la búsqueda
1.
Treatment of bone metastases from solid tumors with bone-modifying agents: a web survey of Italian oncologists investigating patterns of practice drug prescription and prevention of side effects.
Support Care Cancer
; 32(3): 202, 2024 Mar 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-38427111
2.
Italian position paper (SIPMO-SICMF) on medication-related osteonecrosis of the jaw (MRONJ).
Oral Dis
; 2024 Feb 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-38317291
3.
Immune Dysfunction in Medication-Related Osteonecrosis of the Jaw.
Int J Mol Sci
; 24(9)2023 Apr 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-37175652
4.
MRONJ in breast cancer patients under bone modifying agents for cancer treatment-induced bone loss (CTIBL): a multi-hospital-based case series.
BMC Oral Health
; 23(1): 71, 2023 02 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-36739399
5.
One changing and challenging scenario: the treatment of cancer patients with bone metastases by bisphosphonates and denosumab, the cost-benefit evaluation of different options, and the risk of medication-related osteonecrosis of the jaw (MRONJ).
Support Care Cancer
; 30(9): 7047-7051, 2022 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-35312858
6.
The preventive care of medication-related osteonecrosis of the jaw (MRONJ): a position paper by Italian experts for dental hygienists.
Support Care Cancer
; 30(8): 6429-6440, 2022 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-35292850
7.
Correction to: Standard (8 weeks) vs long (12 weeks) timing to minimally-invasive surgery after NeoAdjuvant Chemoradiotherapy for rectal cancer: a multicenter randomized controlled parallel group trial (TiMiSNAR).
BMC Cancer
; 20(1): 128, 2020 02 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-32066408
8.
Standard (8 weeks) vs long (12 weeks) timing to minimally-invasive surgery after NeoAdjuvant Chemoradiotherapy for rectal cancer: a multicenter randomized controlled parallel group trial (TiMiSNAR).
BMC Cancer
; 19(1): 1215, 2019 12 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-31842784
9.
Prognosis of metastatic bone cancer and myeloma patients and long-term risk of medication-related osteonecrosis of the jaw (MRONJ): some critical points.
Support Care Cancer
; 30(12): 9707-9709, 2022 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-35882670
10.
RE: American Association of Oral and Maxillofacial Surgeons' Position Paper on Medication-Related Osteonecrosis of the Jaws-2022 Update: Quantitative Risk Assessment and Controversial Issues.
J Oral Maxillofac Surg
; 80(12): 1871-1873, 2022 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-36464425
11.
Re: AAOMS Position Paper on Medication-Related Osteonecrosis of the Jaw-2022 Update.
J Oral Maxillofac Surg
; 80(11): 1723-1724, 2022 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-36332990
12.
RE: MEDICATION-RELATED OSTEONECROSIS OF THE JAW (MRONJ)
J Oral Maxillofac Surg
; 80(1): 2-3, 2022 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34666036
13.
Persistence, compliance, discontinuation rates and switch rates in denosumab and bisphosphonate treatment of bone metastases in cancer patients: reasons of switch, osteonecrosis of the jaw (ONJ) and other critical points.
Support Care Cancer
; 29(8): 4185-4186, 2021 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-33634351
14.
Adjuvant denosumab in early breast-cancer.
Lancet Oncol
; 21(3): e124, 2020 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-32135108
15.
Epidemiology, clinical manifestations, risk reduction and treatment strategies of jaw osteonecrosis in cancer patients exposed to antiresorptive agents.
Future Oncol
; 10(2): 257-75, 2014 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-24490612
16.
Management of cancer treatment-induced bone loss in patients with breast and hormone sensitive prostate cancer: AIOM survey.
Tumori
; : 3008916241236279, 2024 Mar 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-38462772
17.
Adjuvant chemotherapy of pT1a and pT1b breast carcinoma: results from the NEMESI study.
BMC Cancer
; 12: 158, 2012 Apr 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-22545982
18.
Definition and estimation of osteonecrosis of jaw (ONJ), and optimal duration of antiresorptive treatment in bone metastatic cancer patients: supplementary data from the denosumab extension study?
Support Care Cancer
; 25(2): 345-349, 2017 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-26961666
19.
Vaccination against SARS-CoV-2 protects from morbidity, mortality and sequelae from COVID19 in patients with cancer.
Eur J Cancer
; 171: 64-74, 2022 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-35704976
20.
A pragmatic window of opportunity to minimise the risk of MRONJ development in individuals with osteoporosis on Denosumab therapy: a hypothesis.
Head Face Med
; 17(1): 25, 2021 Jul 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-34243807